iShares Biotechnology (IBB) Intel
Global Biotech Innovators • Tech & Innovation
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more....
Is the biotech capital of the world moving?
Replimune finally wins FDA approval, the role of tau in Alzheimer's, and more biotech news from The Readout...
STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California?
Boston, with its rising costs, high taxes, and business climate, is losing ground to rivals across the country, sometimes even in biotech....
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $...
STAT+: FDA approves Replimune melanoma drug previously rejected twice
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga....
STAT+: Study reveals new role for tau, a top target for Alzheimer’s drug development
The protein tau is top target for Alzheimer’s drug development, and a new study bolsters those efforts by describing a previously unknown role that tau plays in neurodegeneration....
STAT+: Two FDA approvals — a new drug and a new vaccine
Takeda's narcolepsy drug approved, the first mRNA flu shot approved, and more biotech updates from The Readout...
STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more
In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more....
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data hig...
STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year....
STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it
Scientist-turned-biotech executive Greg Verdine is having a very good year....
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions....
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
With a second delayed report of a child's death in China, criticism is rising of a looser form of clinical trial. One expert: what "bothers me is the lack of…...
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
Excluding rare disease therapies from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to new research....
Compiling Intel...